Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic
Platform Enables Vaccines Based On Non-Naturally Occurring VLPs
The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.
You may also be interested in...
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
Ventus raised $60m in series A venture capital 10 months ago when it had just one technology platform. It now has two platforms, five drug development programs and $100m in series B cash.
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.